Pushing Long Acting Injectables During Pregnancy

This piece came out July 23, 2024, so I’m a little late reacting to it. Not only are we going full speed ahead with the prescription of sure to be toxic long acting injectables of “anti-HIV” medications to “HIV” negative individuals, but we’re also very eager to give these medications to pregnant women. What could go wrong?

Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy

We’ve talked about PrEP for pregnant women before, and this is taking the concept to a whole new level.

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study among cisgender women. The analysis of outcomes from more than 300 pregnancies and infants will be presented at the 2024 International AIDS Conference (AIDS 2024) in Munich, Germany.

I’m getting extremely tired of being referred to as a “cisgender woman.” I’m a woman. That’s it. (I always thought “cis” as opposed to “trans” was a nerdy organic chemistry joke, but the story is actually much more sinister.) I’m curious how many women were involved in this study that did not get pregnant, and what kinds of adverse effects they may have experienced.